184 related articles for article (PubMed ID: 23901833)
1. H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.
Price EW; Zeglis BM; Cawthray JF; Ramogida CF; Ramos N; Lewis JS; Adam MJ; Orvig C
J Am Chem Soc; 2013 Aug; 135(34):12707-21. PubMed ID: 23901833
[TBL] [Abstract][Full Text] [Related]
2. H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu.
Price EW; Zeglis BM; Lewis JS; Adam MJ; Orvig C
Dalton Trans; 2014 Jan; 43(1):119-31. PubMed ID: 24104523
[TBL] [Abstract][Full Text] [Related]
3. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
Price EW; Edwards KJ; Carnazza KE; Carlin SD; Zeglis BM; Adam MJ; Orvig C; Lewis JS
Nucl Med Biol; 2016 Sep; 43(9):566-576. PubMed ID: 27419360
[TBL] [Abstract][Full Text] [Related]
4. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
5. H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu.
Bailey GA; Price EW; Zeglis BM; Ferreira CL; Boros E; Lacasse MJ; Patrick BO; Lewis JS; Adam MJ; Orvig C
Inorg Chem; 2012 Nov; 51(22):12575-89. PubMed ID: 23106422
[TBL] [Abstract][Full Text] [Related]
6. H4octapa: an acyclic chelator for 111In radiopharmaceuticals.
Price EW; Cawthray JF; Bailey GA; Ferreira CL; Boros E; Adam MJ; Orvig C
J Am Chem Soc; 2012 May; 134(20):8670-83. PubMed ID: 22540281
[TBL] [Abstract][Full Text] [Related]
7. What a difference a carbon makes: H₄octapa vs H₄C3octapa, ligands for In-111 and Lu-177 radiochemistry.
Price EW; Zeglis BM; Cawthray JF; Lewis JS; Adam MJ; Orvig C
Inorg Chem; 2014 Oct; 53(19):10412-31. PubMed ID: 25192223
[TBL] [Abstract][Full Text] [Related]
8. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
9. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
10. Clinical Dose Preparation of [
Menon SR; Mitra A; Chakraborty A; Tawate M; Sahu S; Rakshit S; Gaikwad S; Dhotre G; Damle A; Banerjee S
Cancer Biother Radiopharm; 2022 Jun; 37(5):384-402. PubMed ID: 35575711
[No Abstract] [Full Text] [Related]
11. Impact of DOTA-Chelators on the Antitumor Activity of
Wojdowska W; Karczmarczyk U; Balog L; Sawicka A; Pöstényi Z; Kovács-Haász V; Polyák A; Laszuk E; Mikołajczak R; Garnuszek P
Cancer Biother Radiopharm; 2020 Oct; 35(8):558-562. PubMed ID: 32255676
[No Abstract] [Full Text] [Related]
12. Synthesis and preclinical evaluation of bifunctional ligands for improved chelation chemistry of 90Y and 177Lu for targeted radioimmunotherapy.
Kang CS; Sun X; Jia F; Song HA; Chen Y; Lewis M; Chong HS
Bioconjug Chem; 2012 Sep; 23(9):1775-82. PubMed ID: 22881720
[TBL] [Abstract][Full Text] [Related]
13. Comparison of bifunctional chelates for (64)Cu antibody imaging.
Ferreira CL; Yapp DT; Crisp S; Sutherland BW; Ng SS; Gleave M; Bensimon C; Jurek P; Kiefer GE
Eur J Nucl Med Mol Imaging; 2010 Nov; 37(11):2117-26. PubMed ID: 20552190
[TBL] [Abstract][Full Text] [Related]
14. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
Bhusari P; Vatsa R; Singh G; Parmar M; Bal A; Dhawan DK; Mittal BR; Shukla J
Int J Cancer; 2017 Feb; 140(4):938-947. PubMed ID: 27813061
[TBL] [Abstract][Full Text] [Related]
15. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
17. Targeting HER2: a report on the in vitro and in vivo pre-clinical data supporting trastuzumab as a radioimmunoconjugate for clinical trials.
Milenic DE; Wong KJ; Baidoo KE; Nayak TK; Regino CA; Garmestani K; Brechbiel MW
MAbs; 2010; 2(5):550-64. PubMed ID: 20716957
[TBL] [Abstract][Full Text] [Related]
18. Radiolanthanide-labeled monoclonal antibody CC49 for radioimmunotherapy of cancer: biological comparison of DOTA conjugates and 149Pm, 166Ho, and 177Lu.
Mohsin H; Jia F; Sivaguru G; Hudson MJ; Shelton TD; Hoffman TJ; Cutler CS; Ketring AR; Athey PS; Simón J; Frank RK; Jurisson SS; Lewis MR
Bioconjug Chem; 2006; 17(2):485-92. PubMed ID: 16536481
[TBL] [Abstract][Full Text] [Related]
19. Radiolabeling of trastuzumab with 177Lu via DOTA, a new radiopharmaceutical for radioimmunotherapy of breast cancer.
Rasaneh S; Rajabi H; Babaei MH; Daha FJ; Salouti M
Nucl Med Biol; 2009 May; 36(4):363-9. PubMed ID: 19423003
[TBL] [Abstract][Full Text] [Related]
20. DOTAGA-trastuzumab. A new antibody conjugate targeting HER2/Neu antigen for diagnostic purposes.
Moreau M; Raguin O; Vrigneaud JM; Collin B; Bernhard C; Tizon X; Boschetti F; Duchamp O; Brunotte F; Denat F
Bioconjug Chem; 2012 Jun; 23(6):1181-8. PubMed ID: 22519915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
